for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover PharmAsia News
  [1 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 1875-7774
   Published by Informa plc Homepage  [16 journals]
  • INTERVIEW: Cook MyoSite Eyes Japan As Cell Therapy Trials Progress
    • Abstract: In the wake of supportive regulations introduced in 2014, more and more firms in the regenerative medicines space are eyeing Japan as an attractive market. US-based Cook MyoSite is no exception.
      PubDate: Tue, 24 May 2016 01:50:01 -040
       
  • Cadila-Hetero Slugfest Over The ‘Hep’ Tag
    • Abstract: Trademark disputes continue unabated in Indian courts, this time involving generic versions of Bristol-Myers Squibb's hepatitis C therapy, Daklinza (daclatasvir) marketed by the local firms Cadila Healthcare and Hetero.
      PubDate: Tue, 24 May 2016 01:10:01 -040
       
  • Samsung Bioepis Taps Infliximab As Its US Biosimilar Pioneer
    • Abstract: A month after the US FDA granted approval of Celltrion's biosimilar infliximab, another South Korean firm, Samsung Bioepis, is rapidly progressing its diverse pipeline and is seeking an entry into the US market through an approval filing for its biosimilar version of the anti-inflammatory antibody. The product is already available in South Korea and recently won a green light in Europe.
      PubDate: Tue, 24 May 2016 01:00:00 -040
       
  • Deep China Price Cuts Reveal Complex Considerations
    • Abstract: Offering deep price discounts in exchange for inclusion in reimbursement lists is never easy, given companies' need to balance expected benefits in volume gains with their international pricing systems and commercial pressures. But in China the underlying considerations are even more complex, as shown by the latest round of national price reductions for selected drugs.
      PubDate: Mon, 23 May 2016 22:25:11 -040
       
  • Japan Pharma Majors Join Hands For Biomarkers
    • Abstract: Indicating the increasing importance of this area to R&D, three major Japanese pharma firms have joined forces for collaborative research on biomarkers.
      PubDate: Mon, 23 May 2016 01:15:00 -040
       
  • ANALYSIS: China Sets The Stage For Its Innovation Entrance
    • Abstract: China is coming up fast on the innovation curve as a result of both political will and a healthy ecosystem that supports R&D. It will take time to challenge the major players from the US and Europe, but there are few that doubt China can, eventually, do so.
      PubDate: Sun, 22 May 2016 20:55:01 -040
       
  • China Busts Counterfeit Plavix Ring In Ongoing Crackdown
    • Abstract: First Viagra, then anticancer drugs, now a best-selling blood thinner. Plavix is the latest target to be unveiled in the nationwide hunt for fake drugs in China, where ring leaders are now using social media to mask their activities and cast a wide net around the vast country, targeting patients taking some of the most prescribed drugs from multinational drug makers.
      PubDate: Fri, 20 May 2016 02:05:00 -040
       
  • GNT’s Multi-Target Stroke Drug Builds Hopes For Longer Window
    • Abstract: GNT Pharma is set to begin a Phase II clinical trial of the world's first multi-target stroke therapy Neu2000, which may propose a new treatment method for ischemic stroke patients who receive revascularization treatment. The South Korean drug developer plans to seek a global licensing out deal for the drug, which is said to sharply extend the time window for stroke treatment, based on the outcome of the study.
      PubDate: Thu, 19 May 2016 22:05:01 -040
       
  • US ANDA Approvals Soar, But Does FDA Need To Do More'
    • Abstract: An industry consultant suggests that the US FDA’s Office of Generic Drugs has to boost its approval volume even higher if it wants to cut its increasing workload.
      PubDate: Thu, 19 May 2016 21:05:01 -040
       
  • India’s New IPR Policy: Balanced And Evolving'
    • Abstract: India’s new National Intellectual Property Rights policy appears to have steered clear of a host of prickly issues pertaining to the pharmaceutical industry for now, while standing firm on the need for "strong measures" against attempts to treat generic drugs as "spurious or counterfeit".
      PubDate: Thu, 19 May 2016 02:30:00 -040
       
  • Halaven Set For China Filing After Positive Results
    • Abstract: Eisai is planning an approval filing for its novel oncology drug in China following positive results in a local breast cancer trial.
      PubDate: Thu, 19 May 2016 01:10:02 -040
       
  • Korean Biotechs Build Early Stage Novel Research
    • Abstract: Novel R&D at several South Korean bioventures is marching on amid the government’s push to nurture the biotech sector. Cellid, ViroMed and Oscotec have all recently unveiled notable progress in their early stage research in immune-oncology, motor neuron disease, and targeted cancer therapy respectively.
      PubDate: Wed, 18 May 2016 22:15:02 -040
       
  • New Chinese JV Confident As It Tackles Inhaled Insulin
    • Abstract: China’s Tonghua Dongbao Pharmaceutical is expanding its diabetes portfolio through a joint venture with Harmony Biopharm for a patented insulin inhaler, aiming to build its presence in the specialized therapeutic area and to expand from an API supplier to a full-range product developer.
      PubDate: Wed, 18 May 2016 21:30:01 -040
       
  • Turkey Pushing Hard For Local Production But Multinationals Cautious
    • Abstract: The Turkish government appears determined in its drive to encourage the localized production of high-value, imported drugs, fueled by the fact that many such products are not now being imported at all due to a low price policy over recent years, and a desire to reduce the import bill. But some observers are worried about a tendency to put pressure on multinational companies to invest.
      PubDate: Wed, 18 May 2016 01:15:00 -040
       
  • First Approval Bodes Well For Hanmi’s Olmutinib
    • Abstract: Hanmi’s novel lung cancer drug olmutinib is set to debut on the South Korean market later this year following its first approval globally after a fast-track review. The therapy will gain a domestic head start over AstraZeneca’s Tagrisso and international licensing deals have already been reached with Boehringer Ingelheim and ZAI Lab.
      PubDate: Tue, 17 May 2016 21:45:01 -040
       
  • Piramal Buys Selected Pfizer OTCs To Pursue Market Leader Goal
    • Abstract: The consumer goods arm of Piramal Enterprises has just made its third acquisition in six months, keeping up a hectic deal-making pace in its quest to be one of India’s leading OTC players.
      PubDate: Tue, 17 May 2016 20:35:02 -040
       
  • Malaysia Exempts Low-Risk Devices From Conformity Assessment
    • Abstract: The Malaysian government exempted all types of Class A (lowest-risk) devices from conformity assessment requirements as of April 18 to make it easier for companies to bring such products to the market. However, these devices will have to continue complying with other regulatory requirements such as labelling and post-marketing commitments.
      PubDate: Tue, 17 May 2016 02:35:01 -040
       
  • Fosun Pitches For India’s Gland
    • Abstract: China’s Shanghai Fosun Pharma has confirmed its interest in the Indian injectables firm Gland Pharma, underscoring how differentiated niche plays continue to attract buyer interest.
      PubDate: Tue, 17 May 2016 01:25:02 -040
       
  • Alteplase Trial Puts ENCHANTED Asian Sites On The Map
    • Abstract: As well as establishing the benefits of lower dosing, new results from a multinational clinical trial with clot-buster alteplase have highlighted the strong performance of Asian study sites, breaking some perceptions in the process.
      PubDate: Tue, 17 May 2016 00:55:01 -040
       
  • Sanofi Optimistic On Dengue Vaccine In India Despite Waiver Blow
    • Abstract: Sanofi believes it can work out a deal with Indian regulators that will not delay access to its new dengue vaccine in the country after a health ministry panel refused its request to waive local Phase III trials.
      PubDate: Mon, 16 May 2016 20:30:02 -040
       
  • Korean Gliptins Loom Amid Signs Of Shifts In India
    • Abstract: A clutch of new dipeptidyl peptidase-4 (DPP-4) inhibitors including LG Life Sciences Ltd's gemigliptin and Dong-A ST Co. Ltd 's evogliptin have either just hit the Indian market or are on the horizon, amid what some industry watchers say are early signs of a volume shake-up in the highly competitive gliptins market.
      PubDate: Mon, 16 May 2016 02:40:01 -040
       
  • Aprogen Turns To IPO To Support Biosimilar Pipeline Expansion
    • Abstract: South Korea's Aprogen, which has reached global partnership with Japan's Nichi-Iko for development of its biosimilar versions of Remicade, Herceptin and Rituxan/Mab Thera, is seeking to independently conduct clinical development of other biosimilar products by using the proceeds from its domestic initial public offering.
      PubDate: Mon, 16 May 2016 02:20:00 -040
       
  • Rising Price Complaints Prompt Renewed China Probes
    • Abstract: Pfizer is reportedly among a clutch of drug makers said to have been summoned to provide information in China's latest investigation of drug prices, which has apparently been prompted by rising public complaints over medicine costs. Chinese regulators could also impose hefty new fines on multinationals if they refuse to provide relevant materials or information, under a draft of revised antitrust regulation.
      PubDate: Mon, 16 May 2016 01:55:01 -040
       
  • Favorable Japan Environment Nurtures Daiichi/CTL Cell Therapy Deal
    • Abstract: Daiichi Sankyo's recent deal for Japan rights to a cell therapy agent illustrates the ongoing corporate appetite for assets able to benefit from the country's favorable regulatory framework for such products.
      PubDate: Mon, 16 May 2016 00:50:00 -040
       
  • Biosimilars In EU Seeing Reduced Clinical Data Requirements
    • Abstract: After a 'slightly conservative approach' at the beginning, 'we are now getting to the meat of what we can do with biosimilars,' the European Medicine Association's Head of Quality Peter Richardson says.
      PubDate: Fri, 13 May 2016 02:55:02 -040
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2015